Next Article in Journal
Acemannan Used as an Implantable Biomaterial for Vital Pulp Therapy of Immature Permanent Teeth Induced Continued Root Formation
Next Article in Special Issue
Uniting Drug and Delivery: Metal Oxide Hybrid Nanotherapeutics for Skin Wound Care
Previous Article in Journal
A Novel Vitamin E TPGS-Based Formulation Enhances Chlorhexidine Bioavailability in Corneal Layers
Previous Article in Special Issue
Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy
 
 
Review

Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers

Drug Transport and Delivery Research Group, Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(7), 643; https://doi.org/10.3390/pharmaceutics12070643
Received: 11 June 2020 / Revised: 2 July 2020 / Accepted: 6 July 2020 / Published: 8 July 2020
(This article belongs to the Special Issue Hybrid Multifunctional Drug Delivery Systems)
Conventional antibiotic therapy is often challenged by poor drug penetration/accumulation at infection sites and poses a significant burden to public health. Effective strategies to enhance the therapeutic efficacy of our existing arsenal include the use of nanoparticulate delivery platforms to improve drug targeting and minimize adverse effects. However, these nanocarriers are often challenged by poor loading efficiency, rapid release and inefficient targeting. Nucleic acid hybrid nanocarriers are nucleic acid nanosystems complexed or functionalized with organic or inorganic materials. Despite their immense potential in antimicrobial therapy, they are seldom utilized against pathogenic bacteria. With the emergence of antimicrobial resistance and the associated complex interplay of factors involved in antibiotic resistance, nucleic acid hybrids represent a unique opportunity to deliver antimicrobials against resistant pathogens and to target specific genes that control virulence or resistance. This review provides an unbiased overview on fabricating strategies for nucleic acid hybrids and addresses the challenges of pristine oligonucleotide nanocarriers. We report recent applications to enhance pathogen targeting, binding and control drug release. As multifunctional next-generational antimicrobials, the challenges and prospect of these nanocarriers are included. View Full-Text
Keywords: nucleic acid nanocarriers; hybrids; bacterial infections; antimicrobial resistance; DNA nanostructures nucleic acid nanocarriers; hybrids; bacterial infections; antimicrobial resistance; DNA nanostructures
Show Figures

Figure 1

MDPI and ACS Style

Obuobi, S.; Škalko-Basnet, N. Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers. Pharmaceutics 2020, 12, 643. https://doi.org/10.3390/pharmaceutics12070643

AMA Style

Obuobi S, Škalko-Basnet N. Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers. Pharmaceutics. 2020; 12(7):643. https://doi.org/10.3390/pharmaceutics12070643

Chicago/Turabian Style

Obuobi, Sybil, and Nataša Škalko-Basnet. 2020. "Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers" Pharmaceutics 12, no. 7: 643. https://doi.org/10.3390/pharmaceutics12070643

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop